Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study DOI Open Access
Mirosława Püsküllüoğlu, Marek Ziobro,

Joanna Lompart

и другие.

Cancers, Год журнала: 2024, Номер 16(16), С. 2894 - 2894

Опубликована: Авг. 20, 2024

The standard therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer includes the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy. optimal post-CDK4/6i treatment sequence is unclear. This cohort study evaluated initiation, characteristics, and outcomes chemotherapy following CDK4/6i-based treatment. Among 227 patients who began CDK4/6i therapy, 114 completed it. Seventy-nine female received further treatment, including 55 receiving chemotherapy. average age was 60.1 years. Post-CDK4/6i typically (69.1%) first-line due to an impending visceral crisis. median progression-free survival (mPFS) 3.0 months (range 0.5–18.9), overall (mOS) 8.3 (0.5–26.1). OS from end 12.4 (1.5–26.8). In univariate analysis, neither mPFS nor mOS associated age, tumor grade, status, Ki67 time diagnosis cessation, line, or type. Dose reduction occurred in 12 (21.8%), ceased adverse events 8 (14.6%). Chemotherapy showed limited benefit regardless regimen. role may evolve broader adjuvant

Язык: Английский

Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study DOI Open Access
Mirosława Püsküllüoğlu, Marek Ziobro,

Joanna Lompart

и другие.

Cancers, Год журнала: 2024, Номер 16(16), С. 2894 - 2894

Опубликована: Авг. 20, 2024

The standard therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer includes the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy. optimal post-CDK4/6i treatment sequence is unclear. This cohort study evaluated initiation, characteristics, and outcomes chemotherapy following CDK4/6i-based treatment. Among 227 patients who began CDK4/6i therapy, 114 completed it. Seventy-nine female received further treatment, including 55 receiving chemotherapy. average age was 60.1 years. Post-CDK4/6i typically (69.1%) first-line due to an impending visceral crisis. median progression-free survival (mPFS) 3.0 months (range 0.5–18.9), overall (mOS) 8.3 (0.5–26.1). OS from end 12.4 (1.5–26.8). In univariate analysis, neither mPFS nor mOS associated age, tumor grade, status, Ki67 time diagnosis cessation, line, or type. Dose reduction occurred in 12 (21.8%), ceased adverse events 8 (14.6%). Chemotherapy showed limited benefit regardless regimen. role may evolve broader adjuvant

Язык: Английский

Процитировано

0